Key takeaways
- Clinical guidelines recommend screening Asian Americans for diabetes at a BMI of 23 due to higher visceral fat risks at lower weights.
- Despite updated clinical guidelines, US insurers still require a standard BMI of 30 (or 27 with comorbidities) to cover GLP-1 medications.
- The clinical trial criteria used to secure FDA approvals disproportionately excluded Asian patients due to Western-centric BMI thresholds.
- The eligibility mismatch is driving many affected Asian American patients to seek compounded GLP-1s and telehealth out-of-pocket.
What happened
A sharp conflict has emerged between clinical screening guidelines and insurance coverage rules for GLP-1 receptor agonists like Wegovy and Zepbound. While the American Diabetes Association (ADA) and global health organizations advocate for lower obesity and diabetes screening thresholds for Asian Americans, standard U.S. insurance policies and clinical trials continue to use rigid Western-centric body mass index (BMI) cutoffs. This regulatory and payer mismatch effectively denies coverage to millions of Asian American patients who carry significant metabolic risks at lower body weights.
Why it matters
For Asian Americans, health risks accumulate at a much lower weight than for individuals of European descent. Research shows that at identical BMI levels, people of Asian heritage tend to carry higher amounts of visceral fat—the dangerous, organ-wrapping fat that drives insulin resistance—and less muscle mass.
Because standard U.S. insurance guidelines require a BMI of 30 (or 27 with a co-morbidity) to cover weight-loss medications, many Asian American patients with clear metabolic risks are shut out of coverage. This clinical disconnect is driving a growing number of patients to seek alternative avenues, such as cash-pay online clinics and compounded alternatives, to access treatment out-of-pocket.
What the data says
The biological mismatch in BMI guidelines is well-documented by medical agencies:
- The Screening Discrepancy: The ADA recommends initiating diabetes screening for Asian Americans at a BMI of 23. Furthermore, the World Health Organization (WHO) identified this risk back in 2004, recommending lower action thresholds of 23 and 27.5 for Asian populations.
- The Real-World Risk: A massive study of 1.5 million adults in England analyzed the BMI at which different ethnic groups reach the same type 2 diabetes risk that white adults reach at a BMI of 30. For South Asian adults, that risk threshold was reached at a BMI of just 23.9, and for Chinese adults, it was 26.9.
- Trial Exclusion Rates: A 2026 analysis of 352 GLP-1 clinical trials revealed that standard BMI entry requirements disproportionately exclude Asian patients. A trial cutoff of 30 BMI made 41.5% of non-Asian American adults eligible, compared to only 13.5% of Asian Americans and 7.2% of Koreans.
- Clinical Trial Success: The 2025 STEP 11 clinical trial, which evaluated semaglutide 2.4 mg (Wegovy) in South Korea and Thailand, utilized the local Asian obesity definition of a BMI of 25 or higher. Participants on the active drug lost 16% of their body weight. A sub-analysis of 68 participants who started with a BMI under 30 showed that those taking semaglutide lost 17.6% of their body weight, compared to just 4.4% on placebo.
- Cardiovascular Benefits: Across eight major cardiovascular outcome trials, GLP-1 therapies prevented a major adverse cardiovascular event in 2.9 out of every 100 Asian participants, compared to 1.4 out of every 100 white participants, demonstrating that Asian patients have some of the most to gain from early intervention.
How it compares
For a consumer looking to buy GLP-1s, the difference in how eligibility is defined can mean thousands of dollars in out-of-pocket expenses.
Under standard insurance policies, a South Asian patient with a BMI of 26.5 and pre-diabetes would typically be denied commercial coverage for weight loss because they do not meet the magic BMI number of 27 or 30. To get the medication, they must pay the full retail cash price for brand-name drugs, which frequently exceeds $1,000 per month for Wegovy or Zepbound.
Because of these barriers, many patients turn to online telehealth platforms. Some platforms specialize in connecting patients to licensed compounding pharmacies. Patients often use our providers portal or compare options directly on our interactive platform to find alternative care.
Compounded semaglutide and tirzepatide typically cost between $200 and $400 per month, representing a savings of up to 70% compared to brand-name cash prices. However, patients must navigate these options carefully. They should review the differences between compounded and brand-name semaglutide to understand the regulatory distinctions, as compounded drugs are not FDA-approved.
How this fits the bigger picture
This eligibility gap highlight a broader shift in the GLP-1 landscape where consumer demand is outpacing traditional insurance coverage. As discussed in our report on how GLP-1 weight loss use has overtaken all other medical uses, weight management is now the primary driver of the market. However, as insurance companies face massive financial pressure, they are tightening, rather than loosening, their coverage criteria.
As we explore in our analysis of how JAMA studies link surgery to lower downstream costs than GLP-1s, insurers are searching for reasons to restrict GLP-1 access to protect their bottom lines. By maintaining rigid, Western-centric BMI cutoffs of 30 and 27, insurance payers can easily deny coverage to marginally overweight patients—even when clinical bodies like the ADA state that those patients are medically obese relative to their ethnic background.
What happens next
The FDA has begun to update some drug labels. For instance, the revised 2026 label for Wegovy and the label for Zepbound have removed specific BMI numbers from their primary indication statements, referring instead to "adults with obesity" or "adults with overweight" alongside a co-morbidity.
However, insurance payers and automated prior authorization systems still rely on the older, rigid BMI numbers (30 and 27) derived from the original clinical trials. Advocates and medical societies continue to pressure U.S. insurers to adopt the ADA’s updated Standards of Care, which require clinicians to confirm excess adiposity using ethnicity-appropriate cutoffs. Until these insurance policies catch up to the clinical science, online telehealth and out-of-pocket cash pay will remain the primary path to treatment for many Asian American patients.
CompareRx does not provide medical advice. Always consult a qualified healthcare provider to determine the best treatment plan for your individual health needs.